(Q44287903)

English

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model

scientific article published in January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model (English)

1 reference

Europe PubMed Central

1 December 2017

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

1 December 2017

author name string

Shaish A

2

1 reference

Europe PubMed Central

1 December 2017

Yacov N

3

1 reference

Europe PubMed Central

1 December 2017

Levkovitz H

4

1 reference

Europe PubMed Central

1 December 2017

Trestman S

5

1 reference

Europe PubMed Central

1 December 2017

Gerber Y

6

1 reference

Europe PubMed Central

1 December 2017

Cohen H

7

1 reference

Europe PubMed Central

1 December 2017

Dvir A

8

1 reference

Europe PubMed Central

1 December 2017

Rhachmani R

9

1 reference

Europe PubMed Central

1 December 2017

Ravid M

10

1 reference

Europe PubMed Central

1 December 2017

Harats D

11

1 reference

Europe PubMed Central

1 December 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

1 December 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

1 December 2017

5

1 reference

Europe PubMed Central

1 December 2017

45-50

1 reference

Europe PubMed Central

1 December 2017

1

1 reference

Europe PubMed Central

1 December 2017

Diabetes and ischemic heart disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00240.X

21 January 2018

Identifiers

10.1046/J.1463-1326.2003.00240.X

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44287903&oldid=2109165469"